Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034321 | PMC |
| http://dx.doi.org/10.3389/fphys.2023.1166761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis.
Rheumatol Ther
January 2025
Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Introduction: Ozoralizumab (OZR) is a novel tumor necrosis factor (TNF) inhibitor that was launched in Japan for treating patients with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. This post-hoc analysis aimed to compare the efficacy of OZR administered without methotrexate (MTX) with placebo or OZR administration in combination with MTX.
Methods: We analyzed the OZR group (30 mg) in the NATSUZORA trial (non-MTX, open trial) (OZR group; n = 94) and the placebo group (MTX group; n = 75) and the 30-mg OZR group (OZR + MTX group; n = 152) in the OHZORA trial (combined MTX, double-blind trial), and the covariates were adjusted by propensity score matching.
Unmasking the Culprit: Reframing Pain in Research and Management of Patellofemoral Pain.
J Orthop Sports Phys Ther
February 2025
This editorial draws an analogy between the literary genre of the 'whodunit' and the complexities of patellofemoral pain (PFP). Traditionally, PFP management has centered on biomechanical factors such as hip muscle weakness, foot pronation, and patellar tracking issues. However, long-term outcomes often remain unsatisfactory, highlighting the need for alternative strategies.
View Article and Find Full Text PDFAndexanet alfa: trials just leave us with more questions.
Res Pract Thromb Haemost
January 2025
Department of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor (ANNEXA-I), the first ever randomized controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomized patients with intracranial hemorrhage to andexanet alfa or usual care, was mandated by the United States Food and Drug Administration as part of its conditional approval in 2018. This approval was originally based on the single-arm trial, The Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors (ANNEXA-4).
View Article and Find Full Text PDFHigh-level production of free fatty acids from lignocellulose hydrolysate by co-utilizing glucose and xylose in yeast.
Synth Syst Biotechnol
June 2025
Division of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian, 116023, PR China.
Lignocellulose bio-refinery via microbial cell factories for chemical production represents a renewable and sustainable route in response to resource starvation and environmental concerns. However, the challenges associated with the co-utilization of xylose and glucose often hinders the efficiency of lignocellulose bioconversion. Here, we engineered yeast to effectively produce free fatty acids from lignocellulose.
View Article and Find Full Text PDFDual physiological responsive structural color hydrogel particles for wound repair.
Bioact Mater
April 2025
Joint Centre of Translational Medicine, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Hydrogel-based patches have demonstrated their values in diabetic wounds repair, particularly those intelligent dressings with continuous repair promoting and monitoring capabilities. Here, we propose a type of dual physiological responsive structural color particles for wound repair. The particles are composed of a hyaluronic acid methacryloyl (HAMA)-sodium alginate (Alg) inverse opal scaffold, filled with oxidized dextran (ODex)/quaternized chitosan (QCS) hydrogel.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!